GlassScriptPhysician profile
George Gabriel Abdelsayed
NPI 1144298613
$19,306.15
in general payments reported to CMS, 2019-2025
23 companies · $5,417 in 2025
The $5,417 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $329 · 2021: $310 · 2022: $346 · 2023: $1,050 · 2024: $11K · 2025: $5,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $5,178 · Consulting Fee: $3,525 · Travel and Lodging: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $5,178.41 |
| Consulting Fee | $3,525.00 |
| Travel and Lodging | $1,343.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $9,423.60 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $5,428.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $1,377.64 | 2020-2025 | Epclusa, Livdelzi, Vemlidy |
| Abbvie INC. | $714.74 | 2019-2024 | Mavyret, Rinvoq |
| Mallinckrodt Hospital Products INC. | $372.06 | 2023-2025 | Terlivaz |
| Pfizer INC. | $353.25 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.15 | 2019-2024 | Xifaxan |
| Shionogi INC | $242.19 | 2019 | |
| Ironwood Pharmaceuticals, INC | $134.20 | 2024 | |
| Cook Medical LLC | $125.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2023 | |
| Intercept Pharmaceuticals, INC. | $124.90 | 2025 | |
| Allergan, INC. | $122.22 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $117.18 | 2021 | |
| Alcresta Therapeutics, INC. | $117.11 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $57.09 | 2025 | |
| Mirum Pharmaceuticals, INC. | $24.21 | 2025 | Livmarli |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.70 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.36 | 2024 | Bylvay |
| Medtronic, INC. | $20.93 | 2024 | Endoflip |
| Janssen Scientific Affairs, LLC | $20.92 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.33 | 2019 | |
| Amgen INC. | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Abdelsayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.